Anti–tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: A case report Philip V. Hassard, Scott W. Binder, Viera.

Slides:

Advertisements

Similar presentations

Serum immunoglobulin a from patients with celiac disease inhibits human T84 intestinal crypt epithelial cell differentiation Tuula Halttunen, Markku Mäki.

Advertisements

Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome Hans Törnblom, Greger Lindberg, Björn Nyberg,

Hyaluronic acid skin fillers: Adverse reactions and skin testing

Uncovering Pathogenic Mechanisms of Inflammatory Bowel Disease Using Mouse Models of Crohn’s Disease–Like Ileitis: What is the Right Model? Fabio Cominelli,

Endoscopic Confocal Imaging

H&E and immunohistochemical (IHC) staining for CD68/CD21, CD3/CD20 and CD117 on colonic mucosa of patients with inflammatory bowel disease (IBD) in disease.

Carlo Catassi, Italo Bearzi, Geoffrey K.T. Holmes Gastroenterology

Cutaneous vasculitis in two patients taking an herbal supplement containing black cohosh Adam Ingraffea, BA, Kevin Donohue, MD, Caroline Wilkel, MD,

Immunopathological characterization of selected mouse models of inflammatory bowel disease: Comparison to human disease Yava L. Jones-Hall, Matthew B.

Volume 120, Issue 4, Pages (March 2001)

Y. Huang, X.-F. Tian, X.-G. Fan, C.-Y. Fu, C. Zhu

Surveillance of Dysplasia in Inflammatory Bowel Disease: The Gastroenterologist- Pathologist Partnership David T. Rubin, Jerrold R. Turner Clinical Gastroenterology.

Ghazaleh Aram, Theodore M. Bayless, Zong–Ming Chen, Elizabeth A

First successful treatment of a primary high-grade gastric MALT lymphoma by eradication therapy for Helicobacter pylori Stephan Timm, Marco Sailer, Karl–hermann.

Seven cases of complete and incomplete forms of Churg-Strauss syndrome not related to leukotriene receptor antagonists Androniki Bili, MD, John J. Condemi,

Volume 122, Issue 2, Pages (February 2002)

Diagnosis of irritable bowel syndrome

Diagnosis of celiac sprue

Outcome analysis in Crohn’s disease using endomicroscopy: How important and reliable is in vivo analysis of microscopic changes? Ralf Kiesslich, MD,

Diverticular Disease–Associated Segmental Colitis

Volume 129, Issue 1, Pages (July 2005)

Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug- induced cutaneous eruptions Nikhil Yawalkar, MD, Maithili Shrikhande,

Case Rep Gastroenterol 2014;8: DOI: /

Malabsorption Work-up: Utility of Small Bowel Biopsy

Adult Autoimmune Enteropathy: Mayo Clinic Rochester Experience

Maya Srivastava, Antonio Perez–Atayde, Maureen M. Jonas

Volume 132, Issue 3, Pages (March 2007)

The emerging role of histologic disease activity assessment in ulcerative colitis Rish K. Pai, MD, PhD, Vipul Jairath, MD, PhD, Niels Vande Casteele,

Laurent Peyrin–Biroulet, Aude Bressenot, Wendy Kampman

Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn’s Disease Elana A. Maser, Renata Villela,

Volume 125, Issue 4, Pages (October 2003)

Endoscopic Confocal Imaging

Wireless capsule endoscopy for obscure small-bowel disorders: Final results of the first pediatric controlled trial Ana Maria Guilhon de Araujo Sant’Anna,

Volume 1, Issue 4, Pages (July 2015)

Ian R. Gooding, Roger Springall, Ian C. Talbot, David B.A. Silk

Volume 130, Issue 2, Pages (February 2006)

Dysfunctional LAD-1 neutrophils and colitis

Beyond Standard Image-enhanced Endoscopy Confocal Endomicroscopy

Volume 120, Issue 4, Pages (March 2001)

Issue Highlights Clinical Gastroenterology and Hepatology

Linear IgA dermatosis after infliximab infusion for ulcerative colitis

Management strategies for dysphagia with a normal-appearing esophagus

Dustin G. James, Gary R. Zuckerman, Gregory S. Sayuk, Hanlin L

Diagnosis of Colitis: Making the Initial Diagnosis

Volume 4, Issue 3, Pages (March 2019)

Melia Hernandez Holt, MD, Vincent Liu, MD, Janet Fairley, MD

Acute generalized exanthematous pustulosis induced by mifepristone

Volume 120, Issue 4, Pages (March 2001)

Volume 129, Issue 1, Pages (July 2005)

Volume 128, Issue 4, Pages (April 2005)

Volume 121, Issue 6, Pages (December 2001)

Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome Hans Törnblom, Greger Lindberg, Björn Nyberg,

Gastrointestinal Endoscopy Volume 46, Issue 3, Pages (September 1997)

AGA technical review on celiac sprue

Volume 121, Issue 5, Pages (November 2001)

A patient with improvement of ulcerative colitis after appendectomy

Ischemic colitis during treatment with alosetron

Volume 126, Issue 2, Pages (February 2004)

Volume 116, Issue 5, Pages (May 1999)

Volume 121, Issue 2, Pages (August 2001)

AGA technical review on osteoporosis in gastrointestinal diseases

Volume 117, Issue 4, Pages (October 1999)

Amebic colitis simulating ulcerative colitis

David S. Fefferman, Richard J. Farrell

Predictors of response to infliximab in patients with Crohn's disease

Volume 120, Issue 4, Pages (March 2001)

Volume 121, Issue 2, Pages (August 2001)

Lack of an association of anisakiasis and inflammatory fibroid polyps

Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy Trevor Markham, MD, Ronan Mullan,

Paraneoplastic Brachial Plexopathy in a Patient With Hodgkin's Disease

Presentation transcript:

Anti–tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: A case report Philip V. Hassard, Scott W. Binder, Viera Nelson, Eric A. Vasiliauskas Gastroenterology Volume 120, Issue 4, Pages 995-999 (March 2001) DOI: 10.1053/gast.2001.22556 Copyright © 2001 American Gastroenterological Association Terms and Conditions

Fig. 1 BD involving the cecum and terminal ileum. Endoscopic view of (A) cecum and (B) terminal ileum before infliximab. Note improvement in deep ulcerations and inflammation 9 weeks later in the (C) cecum and (D) terminal ileum. Gastroenterology 2001 120, 995-999DOI: (10.1053/gast.2001.22556) Copyright © 2001 American Gastroenterological Association Terms and Conditions

Fig. 2 Histologic appearance of colon before and 9 weeks after infliximab. Note the marked reduction of inflammatory cells after the infusion. (A) Low magnification of the colonic mucosa showing distorted crypt architecture with a moderately increased mixed inflammatory cell infiltrate. (B) High magnification showing inflammatory infiltrate consisting of a mixture of neutrophils, lymphocytes, plasma cells, and eosinophils. Blood vessels exhibiting fibrinoid necrosis and perivascular infiltrates can be seen (arrow). (C) Posttreatment biopsy specimen of colonic mucosa shows restoration to normal crypt architecture and normal inflammatory cell infiltrate. Gastroenterology 2001 120, 995-999DOI: (10.1053/gast.2001.22556) Copyright © 2001 American Gastroenterological Association Terms and Conditions

Fig. 3 Inflammatory bowel disease activity indices used to measure response to infliximab infusions (arrows) in a case of BD. (A) CDAI. A CDAI score < 150 points (horizontal line) is considered clinical remission in a patient with CD. (B) IBDQ. IBDQ composite scores range from 32 to 224, with higher scores indicating better QOL. Patients in remission tend to score above 170 (horizontal line). Gastroenterology 2001 120, 995-999DOI: (10.1053/gast.2001.22556) Copyright © 2001 American Gastroenterological Association Terms and Conditions